Patents Assigned to Rosetta Genomics Ltd
  • Publication number: 20140336241
    Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Application
    Filed: July 30, 2014
    Publication date: November 13, 2014
    Applicant: ROSETTA GENOMICS LTD.
    Inventors: Ayelet CHAJUT, Shai ROSENWALD
  • Patent number: 8883757
    Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
    Type: Grant
    Filed: November 20, 2011
    Date of Patent: November 11, 2014
    Assignee: Rosetta Genomics Ltd.
    Inventor: Noga Yerushalmi
  • Publication number: 20140315739
    Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Applicant: ROSETTA GENOMICS LTD.
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald
  • Publication number: 20140309123
    Abstract: The present invention provides specific nucleic acid sequences for use in the identification, classification and diagnosis of various sub-types of lung cancers. The present invention permits one to accurately classify lung cancers based on their miR expression profile without further manipulation. Using microRNA microarray data generated from over two hundred formalin-fixed paraffin-embedded (FFPE) resection samples, fine needle aspiration (FNA) samples and fine needle biopsy (FNB) samples of primary lung cancer, microRNA expression profiles were identified that differ significantly for various sub-types of lung cancer.
    Type: Application
    Filed: March 26, 2012
    Publication date: October 16, 2014
    Applicant: Rosetta Genomics Ltd.
    Inventors: Gila Lithwick Yanai, Hila Benjamin
  • Publication number: 20140256789
    Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicants: YEDA RESEARCH AND DEVELOPMENT COMPANY LTD., ROSETTA GENOMICS, LTD.
    Inventors: Moshe Oren, Nina Raver-Shapira, Efi Marciano, Yael Spector
  • Patent number: 8822144
    Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: September 2, 2014
    Assignee: Rosetta Genomics Ltd.
    Inventors: Ayelet Chajut, Shai Rosenwald
  • Publication number: 20140243230
    Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 28, 2014
    Applicants: Tel Hashomer Medical Research Infrastructure and Services Ltd., Rosetta Genomics Ltd.
    Inventors: Nitzan ROSENFELD, Yael Spector, Eddie Friedman, Zohar Dotan
  • Patent number: 8802599
    Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: August 12, 2014
    Assignee: Rosetta Genomics, Ltd.
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald
  • Publication number: 20140206777
    Abstract: The invention provides a method of diagnosing Alzheimer's disease (AD) in a subject by determining the level of expression of one or more miRNAs molecules associated with AD, as well as various nucleic acid molecules relating thereto or derived thereof.
    Type: Application
    Filed: August 14, 2012
    Publication date: July 24, 2014
    Applicant: ROSETTA GENOMICS LTD.
    Inventor: Yaron Goren
  • Publication number: 20140206854
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Application
    Filed: January 30, 2014
    Publication date: July 24, 2014
    Applicants: ROSETTA GENOMICS LTD., REGULUS THERAPEUTICS INC.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 8765702
    Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: July 1, 2014
    Assignees: Rosetta Genomics Ltd., Yeda Research and Development Company Ltd.
    Inventors: Moshe Oren, Nina Raver-Shapira, Efi Marciano, Yael Spector
  • Publication number: 20140179757
    Abstract: Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.
    Type: Application
    Filed: June 6, 2013
    Publication date: June 26, 2014
    Applicant: ROSETTA GENOMICS, LTD.
    Inventors: Issac Bentwich, Amir Avniel, Ranit Aharonov, Yael Karov, Yonat Shemer-Avni, Asaf Levy
  • Publication number: 20140087967
    Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.
    Type: Application
    Filed: October 25, 2013
    Publication date: March 27, 2014
    Applicants: Mor Research Applications, Rosetta Genomics Ltd.
    Inventors: Yaron GOREN, Shlomit Gilad, Moshe Hod, Yariv Yogev
  • Patent number: 8680067
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: March 25, 2014
    Assignees: Regulus Therapeutics, Inc., Rosetta Genomics Ltd
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 8580503
    Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: November 12, 2013
    Assignees: Rosetta Genomics Ltd., Mor Research Applications
    Inventors: Yaron Goren, Shlomit Gilad, Moshe Hod, Yariv Yogev
  • Patent number: 8563252
    Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of nonsmall-cell lung cancers (NSCLC). The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: October 22, 2013
    Assignee: Rosetta Genomics Ltd.
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald, Hila Benjamin
  • Patent number: 8481506
    Abstract: Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: July 9, 2013
    Assignee: Rosetta Genomics, Ltd.
    Inventors: Issac Bentwich, Amir Avniel, Ranit Aharonov, Yael Karov, Yonat Shemer-Avni, Asal Levy
  • Patent number: 8461315
    Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: June 11, 2013
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Benwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 8455633
    Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: June 4, 2013
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 8389486
    Abstract: Described herein are compositions and methods for the prevention and treatment of hematopoietic malignancies. The compositions are miRNAs and associated nucleic acids.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: March 5, 2013
    Assignees: Rosetta Genomics, Ltd, Immune Disease Institute
    Inventors: Judy Lieberman, Francisco Navarro